Value Creationintermediate

EPS Accretion and Dilution

A project or acquisition is EPS accretive when it raises earnings per share and dilutive when it lowers it. The outcome depends on the financing. For an equity-funded deal, EPS rises when the project’s ROE exceeds the buyer’s earnings yield $E/P$ , because new shares only add value per share if the earnings they bring outpace the price paid for them. For a debt-funded deal, EPS rises when the project’s IRR exceeds the after-tax cost of debt. Crucially, accretion is an accounting outcome, not value creation: a high P/E firm can make a negative-NPV project look accretive because a low $E/P$ is an easy bar to clear.

Why it matters

EPS is profit sliced across a share count, so anything that changes either the numerator or the denominator can move it. Issue shares to fund a project and you add earnings on top but spread them over more shares. Whether EPS rises comes down to a race between the extra earnings and the extra shares, which is exactly the contest between the project’s ROE and the firm’s earnings yield. The trap is that this accounting test uses $E/P$ , not the true cost of equity, so a richly valued firm can clear it while still failing the value test.

Formulas

Equity financing: the accretion test

\text{Accretive} \iff \mathrm{ROE}_{\text{project}} > \dfrac{E}{P}

A share-funded project lifts EPS when its return on the new equity beats the buyer’s earnings yield

E/P

, the reciprocal of the P/E ratio.

E/P

is usually well below the true cost of equity.

Debt financing: the accretion test

\text{Accretive} \iff \mathrm{IRR}_{\text{project}} > r_d (1 - \tau)

A debt-funded project lifts EPS when its internal rate of return exceeds the after-tax cost of debt. Here

r_d

is the borrowing rate and

\tau

the tax rate.

Worked examples

Scenario

A firm earns net income of A$1m on 100,000 shares, so EPS is A$10, and trades at a P/E of 20, a price of A$200. It issues 10,000 new shares to raise A$2m for a project that adds A$300,000 of after-tax earnings. Is the deal accretive, and is it value-creating?

Solution

New shares are 10,000 (A$2m at A$200), so the total is 110,000. New net income is A$1.3m, and new EPS is A$1.3m over 110,000, about A$11.82, up from A$10, so the deal is accretive. The project ROE is A$0.3m over A$2m, that is 15 percent, comfortably above the E/P of 1 over 20, that is 5 percent. Yet accretion does not prove value. If the true cost of equity were 16 percent, the 15 percent project return would still destroy value despite lifting EPS, which is the high P/E trap.

Common mistakes

✗EPS accretion means the deal creates value. Accretion is an accounting effect on earnings per share. A project can lift EPS yet earn less than the true cost of equity and destroy value.
✗Issuing shares always dilutes EPS. Issuing shares dilutes EPS only when the project’s ROE falls short of the firm’s earnings yield. A high-return project funded by equity can be accretive.
✗The accretion bar is the cost of equity. The equity-financing test uses the earnings yield $E/P$ , which is typically far below the cost of equity, so it is an easier and misleading hurdle.
✗Debt and equity deals are judged the same way. A debt-funded project is tested by IRR against the after-tax cost of debt, while an equity-funded one is tested by ROE against $E/P$ .

Revision bullets

•Accretive raises EPS, dilutive lowers it
•Equity financing: accretive when project ROE exceeds the earnings yield E/P
•Debt financing: accretive when project IRR exceeds the after-tax cost of debt
•Accretion is an accounting outcome, not proof of value creation
•High P/E firms can make negative-NPV projects look accretive
•The E/P bar is usually well below the true cost of equity

Quick check

A project funded by issuing new shares will be EPS accretive when

Why can a high P/E firm make a value-destroying project look EPS accretive?

Connected topics

Cost of Debt ROIC vs WACC Managerial Myopia Capital Rationing P/E Ratio

Sources

Titman & Martin, Ch. 7
Titman, S., & Martin, J. D. Valuation: The Art and Science of Corporate Investment Decisions. Pearson.
Develops the EPS accretion and dilution tests for equity and debt financing and the high P/E trap.
Koller, Goedhart & Wessels (2020)
Koller, T., Goedhart, M., & Wessels, D. Valuation: Measuring and Managing the Value of Companies. 7th ed. McKinsey & Company / Wiley, 2020.
Argues that EPS accretion or dilution is a poor guide to whether a transaction creates value.

How to cite this page

Dr. Phil's Quant Lab. (2026). EPS Accretion and Dilution. Derivatives Atlas. https://phucnguyenvan.com/concept/sabv-eps-accretion-dilution

← Back to the atlas See in the network →